Asim Afaq1, Suliman Alahmed2, Shih-Hsin Chen1,3, Thabo Lengana4, Athar Haroon5, Heather Payne6, Hashim Ahmed7, Shonit Punwani8,9, Mike Sathekge4, Jamshed Bomanji10. 1. Institute of Nuclear Medicine, University College London Hospital, London, United Kingdom. 2. Department of Radiology and Medical Imaging, King Khalid University Hospital, Riyadh, Saudi Arabia. 3. Department of Nuclear Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan. 4. Department of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Pretoria, South Africa. 5. Department of Nuclear Medicine, St. Bartholemew's Hospital, Barts Health NHS Trust, London, United Kingdom. 6. Department of Oncology, University College London Hospital, London, United Kingdom. 7. Department of Urology, University College London Hospital, London, United Kingdom. 8. Centre for Medical Imaging, University College London, London, United Kingdom; and. 9. Department of Radiology, University College London Hospital, London, United Kingdom. 10. Institute of Nuclear Medicine, University College London Hospital, London, United Kingdom jamshed.bomanji@nhs.net.
Abstract
The objective of this study was to assess the impact of 68Ga-prostate-specific membrane antigen (68Ga-PSMA) PET/CT on the management of prostate cancer in patients with biochemical recurrence (BCR). Methods: Documented management plans before and after 68Ga-PSMA PET/CT in 100 patients with BCR were retrospectively reviewed, and changes in plans were recorded. Results: Management changed after 68Ga-PSMA PET/CT in 39 patients (39%). The management changes occurred in 23 (33.8%) of 68 patients with radical prostatectomy and 16 (50%) of 32 patients previously treated with radical radiotherapy. Positive scan results (P < 0.001) and higher prostate-specific antigen (PSA) levels (P = 0.024) were associated with management changes. No significant association with management change was found for Gleason grade, stage, presence of metastatic disease, PSA velocity, or PSA doubling time. Conclusion: 68Ga-PSMA PET/CT altered management in 39% of patients with BCR, and changes occurred more often in patients with radical radiotherapy treatment, positive 68Ga-PSMA scan results, and higher PSA levels.
The objective of this study was to assess the impact of 68Ga-prostate-specific membrane antigen (68Ga-PSMA) PET/CT on the management of prostate cancer in patients with biochemical recurrence (BCR). Methods: Documented management plans before and after 68Ga-PSMA PET/CT in 100 patients with BCR were retrospectively reviewed, and changes in plans were recorded. Results: Management changed after 68Ga-PSMA PET/CT in 39 patients (39%). The management changes occurred in 23 (33.8%) of 68 patients with radical prostatectomy and 16 (50%) of 32 patients previously treated with radical radiotherapy. Positive scan results (P < 0.001) and higher prostate-specific antigen (PSA) levels (P = 0.024) were associated with management changes. No significant association with management change was found for Gleason grade, stage, presence of metastatic disease, PSA velocity, or PSA doubling time. Conclusion: 68Ga-PSMA PET/CT altered management in 39% of patients with BCR, and changes occurred more often in patients with radical radiotherapy treatment, positive 68Ga-PSMA scan results, and higher PSA levels.
Authors: Thomas A Hope; Jeremy Z Goodman; Isabel E Allen; Jeremie Calais; Wolfgang P Fendler; Peter R Carroll Journal: J Nucl Med Date: 2018-12-07 Impact factor: 10.057
Authors: Thorsten Derlin; Sebastian Schmuck; Cathleen Juhl; Johanna Zörgiebel; Sophie M Schneefeld; Almut C A Walte; Katja Hueper; Christoph A von Klot; Christoph Henkenberens; Hans Christiansen; James T Thackeray; Tobias L Ross; Frank M Bengel Journal: Eur J Nucl Med Mol Imaging Date: 2018-01-07 Impact factor: 9.236
Authors: Julian Müller; Daniela A Ferraro; Urs J Muehlematter; Helena I Garcia Schüler; Sarah Kedzia; Daniel Eberli; Matthias Guckenberger; Stephanie G C Kroeze; Tullio Sulser; Daniel M Schmid; Aurelius Omlin; Alexander Müller; Thomas Zilli; Hubert John; Helmut Kranzbuehler; Philipp A Kaufmann; Gustav K von Schulthess; Irene A Burger Journal: Eur J Nucl Med Mol Imaging Date: 2018-11-28 Impact factor: 9.236
Authors: Jeremie Calais; Wolfgang P Fendler; Matthias Eiber; Jeannine Gartmann; Fang-I Chu; Nicholas G Nickols; Robert E Reiter; Matthew B Rettig; Leonard S Marks; Thomas E Ahlering; Linda M Huynh; Roger Slavik; Pawan Gupta; Andrew Quon; Martin S Allen-Auerbach; Johannes Czernin; Ken Herrmann Journal: J Nucl Med Date: 2017-12-14 Impact factor: 10.057
Authors: Wolfgang P Fendler; Jeremie Calais; Matthias Eiber; Robert R Flavell; Ashley Mishoe; Felix Y Feng; Hao G Nguyen; Robert E Reiter; Matthew B Rettig; Shozo Okamoto; Louise Emmett; Helle D Zacho; Harun Ilhan; Axel Wetter; Christoph Rischpler; Heiko Schoder; Irene A Burger; Jeannine Gartmann; Raven Smith; Eric J Small; Roger Slavik; Peter R Carroll; Ken Herrmann; Johannes Czernin; Thomas A Hope Journal: JAMA Oncol Date: 2019-06-01 Impact factor: 31.777
Authors: Ida Sonni; Matthias Eiber; Wolfgang P Fendler; Rejah M Alano; Sitaram S Vangala; Amar U Kishan; Nicholas Nickols; Matthew B Rettig; Robert E Reiter; Johannes Czernin; Jeremie Calais Journal: J Nucl Med Date: 2020-01-10 Impact factor: 10.057
Authors: Stefan A Koerber; Leon Will; Clemens Kratochwil; Matthias F Haefner; Henrik Rathke; Christophe Kremer; Jonas Merkle; Klaus Herfarth; Klaus Kopka; Peter L Choyke; Tim Holland-Letz; Uwe Haberkorn; Juergen Debus; Frederik L Giesel Journal: J Nucl Med Date: 2018-07-05 Impact factor: 10.057